Daan Gene Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Daan Gene.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	43.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Health Check: How Prudently Does Daan Gene (SZSE:002030) Use Debt?

Oct 24

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Aug 20

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

May 02

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Apr 05

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Mar 25

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Mar 06

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Daan Gene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:002030 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	930	-751	270	628	N/A
6/30/2024	1,045	-697	456	838	N/A
3/31/2024	1,038	-295	587	1,051	N/A
12/31/2023	1,181	105	207	780	N/A
9/30/2023	3,553	854	771	1,561	N/A
6/30/2023	5,906	2,221	1,195	2,408	N/A
3/31/2023	9,025	3,769	1,398	2,955	N/A
1/1/2023	12,046	5,412	2,652	4,155	N/A
9/30/2022	11,363	6,004	2,594	4,009	N/A
6/30/2022	10,858	5,615	2,985	3,930	N/A
3/31/2022	8,687	4,170	2,682	3,452	N/A
1/1/2022	7,664	3,618	2,646	3,305	N/A
9/30/2021	7,419	3,436	2,948	3,555	N/A
6/30/2021	6,691	3,268	2,307	2,927	N/A
3/31/2021	7,092	3,391	2,621	2,997	N/A
12/31/2020	5,341	2,449	2,150	2,515	N/A
9/30/2020	3,890	1,549	968	1,030	N/A
6/30/2020	2,715	810	591	663	N/A
3/31/2020	1,435	250	216	293	N/A
12/31/2019	1,098	92	0	93	N/A
9/30/2019	1,060	103	301	397	N/A
6/30/2019	1,190	103	456	551	N/A
3/31/2019	1,343	102	433	529	N/A
12/31/2018	1,479	102	292	392	N/A
9/30/2018	1,575	89	4	119	N/A
6/30/2018	1,575	88	N/A	-117	N/A
3/31/2018	1,581	88	N/A	-190	N/A
12/31/2017	1,542	87	N/A	-220	N/A
9/30/2017	1,609	98	N/A	-95	N/A
6/30/2017	1,594	101	N/A	-365	N/A
3/31/2017	1,627	107	N/A	-415	N/A
12/31/2016	1,613	107	N/A	-381	N/A
9/30/2016	1,638	107	N/A	-379	N/A
6/30/2016	1,636	105	N/A	-145	N/A
3/31/2016	1,536	102	N/A	-68	N/A
12/31/2015	1,474	101	N/A	-6	N/A
9/30/2015	1,322	133	N/A	19	N/A
6/30/2015	1,223	153	N/A	53	N/A
3/31/2015	1,150	153	N/A	34	N/A
12/31/2014	1,086	153	N/A	40	N/A
9/30/2014	1,016	123	N/A	3	N/A
6/30/2014	964	147	N/A	21	N/A
3/31/2014	903	145	N/A	69	N/A
12/31/2013	854	144	N/A	27	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 002030's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 002030's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 002030's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 002030's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 002030's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 002030's Return on Equity is forecast to be high in 3 years time

Daan Gene Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.035 loss in 3Q 2023)

Health Check: How Prudently Does Daan Gene (SZSE:002030) Use Debt?

Daan Gene Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.27 profit in 2Q 2023)

Daan Gene Co., Ltd. (SZSE:002030) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

New minor risk - Share price stability

Daan Gene Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Dividend reduced to CN¥0.015

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Is Daan Gene (SZSE:002030) Weighed On By Its Debt Load?

First quarter 2024 earnings released: CN¥0.26 loss per share (vs CN¥0.026 profit in 1Q 2023)

Daan Gene's (SZSE:002030) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: CN¥0.075 (vs CN¥3.86 in FY 2022)

Daan Gene Co., Ltd., Annual General Meeting, Apr 19, 2024

Calculating The Fair Value Of Daan Gene Co., Ltd. (SZSE:002030)

Daan Gene Co., Ltd. (SZSE:002030) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Now 21% overvalued

Investor sentiment deteriorates as stock falls 15%

Now 20% overvalued

Daan Gene Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: CN¥0.035 loss per share (vs CN¥0.94 profit in 3Q 2022)

Daan Gene Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

New major risk - Dividend sustainability

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥1.36 in 2Q 2022)

Less than half of directors are independent

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Daan Gene Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on June 13, 2023

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: CN¥3.95 (vs CN¥2.58 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.94 (vs CN¥0.66 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.36 (vs CN¥0.33 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.34 (vs CN¥0.33 in 2Q 2021)

Insufficient new directors

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of CN¥1.11 per share

Daan Gene Co., Ltd. Proposes Final Cash Dividend on A Shares for the Year 2021, Payable on May 9, 2022

Insufficient new directors

Daan Gene Co., Ltd. Approves Final Dividend for the Year 2021

Daan Gene Co., Ltd., Annual General Meeting, Apr 20, 2022

Daan Gene Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.66 (vs CN¥0.54 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Da An Gene Co., Ltd. of Sun Yat-Sen University Announces Final Dividend Implementation Plan (A Shares) for 2020, Payable on 19 May 2021

First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.77 (vs CN¥0.10 in FY 2019)

New 90-day low: CN¥29.03

Da an Gene Co., Ltd. of Sun Yat-Sen University Announces Executive Changes

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report Fiscal Year 2020 Results on Mar 31, 2021

Investor sentiment deteriorated over the past week

New 90-day high: CN¥42.15

New 90-day low: CN¥31.98

Third quarter 2020 earnings released: EPS CN¥0.86

First half earnings released

First half earnings released

Da An Gene Co., Ltd. of Sun Yat-Sen University to Report First Half, 2020 Results on Aug 29, 2020

New 90-day high - CN¥40.83

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies